MUC1 and familial pancreatic carcinoma: An open-label phase I study of advanced pancreatic cancer showed that recombinant prime-boost poxviruses (targeting MUC1 and carcinoembryonic antigen prolonged the overall survival of patients with anti-MUC1 and/or carcinoembryonic antigen-specific immune responses [66].